|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | - | Perf Week | -24.42% |
Market Cap | - | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 30.73M | Perf Month | -24.42% |
Income | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | -87.81% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | -87.96% |
Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 0.14 - 3.00 | Perf YTD | -83.57% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -93.70% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 34.96% | ATR | 0.07 |
Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 37.44 | Volatility | 11.83% 19.28% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.00 | Prev Close | 0.19 |
Shortable | No | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 16.34K | Price | 0.19 |
Recom | - | SMA20 | -29.48% | SMA50 | -73.74% | SMA200 | -83.78% | Volume | 0 | Change | 0.00% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite